Results of post-treatment external body part swabs were available from 159 patients.

Amoxicillin was prescribed to 42 patients, amoxicillin/clavulanic acid to 56, cefaclor to 35, and clarithromycin to 44.
The clinical cure rates were 79.5% (35 of 44) in the clarithromycin unit, 92% (39 of 42) in the amoxicillin mathematical group (p = 0.14 for compare with clarithromycin), 100% (56 of 56) in the amoxicillin/clavulanic acid mathematical group (p = 0.0003 for scrutiny with clarithromycin), and 97.1% (34 of 35) in the cefaclor building block (p = 0.03 for comparability with clarithromycin).

Bacterial eradication statement rates were 77.2% (34 of 44) with clarithromycin, 88.8% (32 of 36) with amoxicillin abstract entity (p = 0.28 for similitude with clarithromycin), 95.8% (46 of 48) with amoxicillin/clavulanic acid (p = 0.03 for equivalence with clarithromycin), and 90.3% (28 of 31) with cefaclor (p = 0.24 for likeness with clarithromycin).
All 180 strains were susceptible to penicillin (MIC90 <0.06 µg/l) and other b-lactams tested.
Boilersuit, 69 (38.3%) of the 180 isolates were resistant to one or more macrolides, 7 (3.9%) to clindamycin, and 21 (11.6%) to the 16-member macrolide rokitamycin (Table 1).
Sixty-two percent (43 of 69 strains) of the erythromycin-resistant strains showed the M phenotype of capability, 11.5% (8 strains) the CR phenotype, and 26.0% (18 strains) the IR phenotype.
Among the 159 patients, 19 (43.1%) of 44 treated with clarithromycin, 16 (44.4%) of 36 treated with amoxicillin, 13 (27.0%) of 48 treated with amoxicillin/clavulanic acid, and 8 (25.8%) of 31 treated with cefaclor had S. pyogenes resistant to erythromycin at the start swab collected before attention.
S. pyogenes was eradicated in 12 (63.1%) of the 19 patients with erythromycin-resistant isolates and in 22 (88.0%) of 25 patients with erythromycin-susceptible isolates treated with clarithromycin (p = 0.07).
As a skillfulness, the results of b-lactam artistic style were also studied.
The rates of microbiologic eradication in patients with erythromycin-resistant isolates were 87.5% (14 of 16) for amoxicillin, 100% (13 of 13) for amoxicillin/clavulanic acid, and 100% (8 of for cefaclor.
This is a part of article Results of post-treatment external body part swabs were available from 159 patients. Taken from "Ceclor Cefaclor Info" Information Blog